All Posts

For three years, biotech investors were told to wait for the cycle to turn. Now that it has, the more interesting question is not whether the recovery is real — it is — but why this one looks so unlike the last. The numbers tell a story of selective vitality rather than indiscriminate exuberance. After a year split brutally in two: a first half frozen by tariff shocks and regulatory upheaval, and a second half that reopened the capital markets with surprising force, the momen

The Current State of Healthcare Investment Before the conflict escalated, global healthcare investing was on an improving trajectory. Biotech had begun to emerge from a two-year slump in April 2025, entering a near-historic run. Drug launches were strong, investor sentiment was favorable, and capital inflows were spiking. Falling interest rates were particularly supportive for unprofitable smaller-cap biotechs. Healthcare private equity deal activity, which had shown an uneve

Blackstone has successfully closed a Life Sciences fund totaling $6.3 billion , marking it as the largest to date. This fund represents a substantial 40% increase over its 2020 predecessor, signifying an intensified strategic focus on biopharmaceutical investments. Key Strategic Implications: This significant capital raise underscores growing investor confidence within the life sciences sector. It further highlights the expanding role of private equity in funding critical d

The ability to make direct investments can be very attractive to family members and those running family office investment portfolios. It can mean investing in areas related to the wealth-creating activities of the family members, or areas in which they have developed a particular interest. Many family offices pursue direct investments with a goal of enhanced returns by avoiding the management fees and carried interest of fund investments, in addition to supporting the family